Gastroretentive fibrous dosage forms for prolonged delivery of sparingly-soluble tyrosine kinase inhibitors. Part 1: Dosage form design, and models of expansion, post-expansion mechanical strength, and drug release (Withdrawal of Vol 653, art no 123428, 2024)

被引：0

作者：

Blaesi, Aron H. ^{[1
,2
]}

Saka, Nannaji ^{[3
]}

机构：

[1] Enzian Pharmaceut Blaesi AG, CH-7078 Lenzerheide, Switzerland

[2] Enzian Pharmaceut Inc, Cambridge, MA 02139 USA

[3] MIT, Dept Mech Engn, Cambridge, MA 02139 USA

来源：

INTERNATIONAL JOURNAL OF PHARMACEUTICS | 2024年 / 653卷

关键词：

D O I：

10.1016/j.ijpharm.2024.124019

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页数：1

共 7 条

[1] Gastroretentive fibrous dosage forms for prolonged delivery of sparingly soluble tyrosine kinase inhibitors. Part 1: Dosage form design, and models of in vitro expansion, post-expansion mechanical strength, and drug release (Withdrawn Publication. See vol. 653, 2024)
Blaesi, Aron H.
Saka, Nannaji
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 653
[2] Gastroretentive fibrous dosage forms for prolonged delivery of sparingly soluble tyrosine kinase inhibitors. Part 2: Experimental validation of the models of in vitro expansion, post-expansion mechanical strength, and drug release
Blaesi, Aron H.
Saka, Nannaji
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 653
[3] Gastroretentive fibrous dosage forms for prolonged delivery of sparingly soluble tyrosine kinase inhibitors. Part 2: Experimental validation of the models of expansion, mechanical strength, and in vitro drug release (Withdrawal of Vol 653, art no 123429, 2024)
Blaesi, Aron H.
Saka, Nannaji
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 653
[4] Gastroretentive fibrous dosage forms for prolonged delivery of sparingly-soluble tyrosine kinase inhibitors. Part 4: Experimental validation of the models of in vivo expansion, gastric residence time, and drug concentration in blood (Withdrawal of Vol 653, art no 123479, 2024)
Blaesi, Aron H.
Saka, Nannaji
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 653
[5] Gastroretentive fibrous dosage forms for prolonged delivery of sparingly soluble tyrosine kinase inhibitors. Part 3: Theoretical models of in vivo expansion, gastric residence time, and drug concentration in blood (Withdrawal of Vol 653, art no 123478, 2024)
Blaesi, Aron H.
Saka, Nannaji
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 653
[6] Gastroretentive fibrous dosage forms for prolonged delivery of sparingly-soluble tyrosine kinase inhibitors. Part 4: Experimental validation of the models of in vivo expansion, gastric residence time, and drug concentration in blood (Withdrawn Publication. See vol. 653, 2024)
Blaesi, Aron H.
Richter, Henning
Saka, Nannaji
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 653
[7] Gastroretentive fibrous dosage forms for prolonged delivery of sparingly soluble tyrosine kinase inhibitors. Part 3: Theoretical models of in vivo expansion, gastric residence time, and drug concentration in blood
Blaesi, Aron H.
Saka, Nannaji
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 653

← 1 →